Nanoscope Therapeutics Highlights MCO-010 at Major Congress
DALLAS — Nanoscope Therapeutics Inc., a leading biotechnology company, is dedicated to creating groundbreaking therapies aimed at restoring vision for those suffering from photoreceptor loss and retinal degeneration. Recently, the company announced notable presentations regarding their optogenetic therapy, MCO-010, which were showcased at the prestigious FLORetina-ICOOR 2025 Congress held in Italy.
Dr. Jordi Monés and Dr. Allen C. Ho highlighted the exciting findings from Phase 2b/3 studies on MCO-010, focusing on its effectiveness as a therapeutic option for patients experiencing severe vision loss due to Retinitis Pigmentosa (RP). The congress, a gathering of prominent experts in vitreoretinal diseases, served as an excellent platform for presenting the therapy's beneficial long-term effects.
Promising Results of MCO-010 Therapy
During the congress, Dr. Jordi Monés expressed enthusiasm regarding the results, stating, "Achieving consistent three-line visual improvement for over three years with a single dose of MCO-010 is extraordinary for patients suffering from Retinitis Pigmentosa." This statement reflects the significant impact that MCO-010 can have on the quality of life for those affected by severe vision impairments.
Details of the Presentations
The details of the presentations included the following:
Title: REMAIN: Long-term Follow-up from RESTORE Evaluating Efficacy and Safety of MCO-010 Optogenetic Therapy
Presenter: Jordi Monés, MD, PhD
Date/Time: December 5 | 9:18 CET
Session: Highlighted Free Papers 2
Location: Del Carmine Room
Title: Efficacy and Safety of MCO-010 in Advanced Retinitis Pigmentosa
Presenter: Allen C. Ho, MD
Date/Time: December 6 | 11:18 CET
Session: Retina Futura - Spotlight on Emerging Therapies
Location: Sante Croce Room
MCO-010: A Game-Changer for Vision Restoration
MCO-010 has received recognition from the FDA with Fast Track and Orphan Drug designations, currently undergoing a rolling Biologics License Application (BLA) for Retinitis Pigmentosa. With approvals in various regions, including multiple Orphan designations from the European Medicines Agency, MCO-010 stands to offer hope to many patients.
This innovative therapy is designed to restore vision through a highly accessible, one-time in-office intravitreal procedure. MCO-010 targets and reactivates the existing retinal cells, which enables patients to regain vision without the need for complex genetic testing or multiple treatments.
About the MCO Platform
The MCO platform is revolutionary, targeting multiple retinal degenerations witnessed in patients suffering from conditions like Stargardt disease and geographic atrophy. By harnessing the remaining retinal circuitry, MCO-010 ensures broad patient applicability, enhancing its potential as a standard approach in retinal treatment.
Nanoscope Therapeutics: Driving Innovation Forward
Nanoscope Therapeutics continues to lead the way in the development of vision-restoring therapies. The success of trials like RESTORE and the upcoming Phase 3 clinical trials signals a transformative change in how retinal diseases are approached. These studies bolster the excitement surrounding MCO-010, which can be administered without the complications often associated with existing therapies.
The company is committed to expanding its research and application scope, with plans to initiate trials for geographic atrophy and other inherited retinal diseases. By 2025, Nanoscope Therapeutics is expected to enhance its efforts and further explore the therapeutic landscape.
Company Contact Information
Nanoscope Therapeutics
(817) 857-1186
For more inquiries, please visit their official website.
Frequently Asked Questions
What is MCO-010?
MCO-010 is an optogenetic therapy designed to restore vision in patients suffering from retinal degenerative diseases like Retinitis Pigmentosa.
What were the results shared at the FLORetina-ICOOR Congress?
The presentation at the congress highlighted sustained visual improvements for over three years in patients after a single dose of MCO-010.
What designations has MCO-010 received?
MCO-010 has been granted FDA Fast Track and Orphan Drug designations, enhancing its potential for approval and use.
Who are the leading figures involved in MCO-010’s development?
Dr. Jordi Monés and Dr. Allen C. Ho are prominent presenters and contributors to research surrounding MCO-010.
When will further trials for MCO-010 start?
Nanoscope Therapeutics plans to begin Phase 3 registrational trials for MCO-010 in the upcoming year, with additional studies in geographic atrophy expected by 2025.
